从分子生物学特征到综合治疗策略:乳头型颅咽管瘤的研究进展  

Recent advance in papillary craniopharyngioma:from molecular biological characteristics to comprehensive treatment strategies

作　　者：罗宁 林懿 洪涛[2] 林志雄[1] Luo Ning;Lin Yi;Hong Tao;Lin Zhixiong(Department of Neurosurgery,Sanbo Brain Hospital,Capital Medical University,Beijing 100093,China;Department of Neurosurgery,First Affiliated Hospital of Nanchang University,Nanchang 330200,China)

机构地区：[1]首都医科大学三博脑科医院神经外科,北京100093 [2]南昌大学第一附属医院神经外科,南昌330200

出　　处：《中华神经医学杂志》2024年第10期1055-1063,共9页Chinese Journal of Neuromedicine

基　　金："十四五"国家重点研发计划(2023YFC2411603);首都卫生发展科研专项项目(2022-2-8013);三博脑科医院管理集团股份有限公司科研立项项目(SBJT-KY-2020-002)。

摘　　要：近年来,关于乳头型颅咽管瘤(PCP)的分子生物学研究已经取得了突破性进展,并依此进行了靶向治疗的临床实践,也取得令人鼓舞的成果。本文现围绕PCP的分子生物学特征尤其是BRAF V600E基因突变机制及其在PCP发生中的作用,以及结合靶向治疗、手术治疗、放疗等多种治疗方式的PCP综合治疗策略的研究进展进行综述,并展望PCP精准治疗方面的未来研究方向,以期为临床同道提供一些参考借鉴。In recent years,molecular biological research on papillary craniopharyngioma(PCP)has made significant breakthrough,leading to the clinical application of targeted therapy,which has yielded encouraging outcome.This article reviews the molecular biological characteristics of PCP,with a particular focus on mechanism of BRAF V600E gene mutation and its role in tumorigenesis.Furthermore,it also summarizes PCP comprehensive treatment strategies combining targeted therapy,surgery,and radiation therapy and proposes future research directions for precision PCP management,aiming at providing some references for clinical colleagues.

关 键 词：乳头型颅咽管瘤 分子生物学 综合治疗策略 靶向治疗 

分 类 号：R739.41[医药卫生—肿瘤]